Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study

Overview

Chronic kidney disease (CKD) and hypertension are two closely related common chronic diseases that have serious implications to human health. Hypertension is a major cause for progression of renal disease and a risk factor for cardiovascular disease (CVD). Control of Blood Pressure (BP) to target is now considered to be the main goal in the treatment of patients with CKD. In clinical practice, it is difficult for CKD patients with hypertension to achieve systolic BP (SBP) or diastolic BP (DBP) goal; oftentimes, calcium channel blocker (CCB) class of drugs, for example, nifedipine gastrointestinal therapeutic system (GITS), is used in such patients. Previous data have demonstrated nifedipine to be having a significant dose-response relationship; that is, nifedipine 60 mg provided better BP reduction than 30 mg. However, there are limited studies that have evaluated the efficacy and tolerability of nifedipine GITS 60 mg in Chinese CKD patients with hypertension. Hereby, the objective of this study was to evaluate the effectiveness and tolerability of nifedipine GITS 60 mg treatment in a large cohort of CKD patients with uncontrolled hypertension.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 14, 2020

Interventions

  • Drug: Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)
    • Nifedipine GITS 60 mg (once per day)

Arms, Groups and Cohorts

  • Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)
    • Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.

Clinical Trial Outcome Measures

Primary Measures

  • Change in office systolic blood pressure from baseline to week 12
    • Time Frame: At week 12
    • Change in office systolic blood pressure from baseline to week 12

Secondary Measures

  • Change in office diastolic blood pressure from baseline to week 12
    • Time Frame: At week 12
    • Change in office diastolic blood pressure from baseline to week 12
  • Change in systolic blood pressure and diastolic blood pressure from baseline to week 12 according to baseline SBP stratification
    • Time Frame: At week 12
    • Change in systolic blood pressure and diastolic blood pressure from baseline to week 12 according to baseline SBP stratification, stratified by two subgroups baseline, SBP 140-160 mmHg and ≥ 160 mmHg
  • Change in systolic blood pressure and diastolic blood pressure from baseline to week 12 at different stages of Chronic Kidney Disease
    • Time Frame: At week 12
    • Change in systolic blood pressure and diastolic blood pressure from baseline to week 12 at different stages of Chronic Kidney Disease, stage 1 to stage 5
  • Systolic blood pressure and diastolic blood pressure control rate at week 12
    • Time Frame: At week 12
    • Systolic blood pressure and diastolic blood pressure control rate at week 12
  • Number of participants with adverse events and serious adverse events
    • Time Frame: At week 12

Participating in This Clinical Trial

Inclusion Criteria

  • Male and female patients aged 18-70 years – Patients diagnosed with CKD (Estimated Glomerular Filtration Rate (eGFR) >15 mL/min/1.73 m*2) and hypertension without dialysis/replacement therapy – Patients with uncontrolled hypertension (office SBP ≥140 mmHg and DBP ≥ 80 mmHg) who have received Renin-Angiotensin System Inhibitors (RASI) treatment or have not received RASI treatment because of any contraindications – Patients who haven't received nifedipine GITS 60 mg (once per day) previously – Patients for whom the decision to initiate treatment with nifedipine GITS 60 mg was made as per the investigator's routine treatment practice – Signed informed consent – No participation in an investigational program with interventions outside of routine clinical practice Exclusion Criteria:

  • Have a contraindication to nifedipine GITS according to the approved prescribing information – Patients participating in an investigational program with interventions outside of routine clinical practice

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bayer Study Director, Study Director, Bayer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.